Anzeige
Mehr »
Login
Freitag, 21.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Warum diese Aktie jetzt massiv durchstartet und wie Sie zu neuen Gratis-Aktien kommen…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
20.06.24
21:54 Uhr
1,026 Euro
-0,016
-1,54 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0181,05409:08
1,0181,05409:08

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAtossa Therapeutics, Inc.: Atossa Set to Join Russell 3000® Index Effective June 28, 202412
05.06.Atossa Therapeutics, Inc.: Atossa to Present at the Sidoti Small-Cap Investor Conference10
28.05.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model12
15.05.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial396SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that the last patient in the Company's Karisma-Endoxifen clinical trial...
► Artikel lesen
13.05.Atossa Therapeutics files for $100M mixed shelf offering16
13.05.Atossa Therapeutics GAAP EPS of -$0.058
13.05.ATOSSA THERAPEUTICS, INC. - 10-Q, Quarterly Report7
13.05.ATOSSA THERAPEUTICS, INC. - 8-K, Current Report4
13.05.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update640Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with...
► Artikel lesen
07.05.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines13
29.04.Atossa Therapeutics announces expanded research agreement with Weill Cornell Medicine13
29.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen148SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced an expanded research agreement with Weill Cornell Medicine to explore...
► Artikel lesen
11.04.Atossa (ATOS) Reports Positive Results From EVANGELINE Study22
11.04.Atossa Therapeutics, Inc.: Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference9
09.04.Atossa stock climbs 11% on breast cancer drug data13
09.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen167SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE...
► Artikel lesen
01.04.Atossa Therapeutics Inc reports results for the quarter ended in December - Earnings Summary32
01.04.Atossa Therapeutics GAAP EPS of -$0.24 in-line5
01.04.Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update156Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study...
► Artikel lesen
01.04.ATOSSA THERAPEUTICS, INC. - 10-K, Annual Report1
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,9